Two-Year Clinical Outcomes After Enhanced External
... patients who had severe LV dysfunction that was treated with EECP for angina pectoris and reports clinical outcomes, event-free survival rates, and the incidence of repeat EECP. This study included 363 patients who had refractory angina and LV ejection fraction <35%. Most patients reported quality o ...
... patients who had severe LV dysfunction that was treated with EECP for angina pectoris and reports clinical outcomes, event-free survival rates, and the incidence of repeat EECP. This study included 363 patients who had refractory angina and LV ejection fraction <35%. Most patients reported quality o ...
in heart failure Prediction and prevention of sudden cardiac death
... 10–50% from referral centres, with up to 28% of deaths being classified as sudden.6 w2 More recent studies of DCM patients on optimal medical treatment have reported considerably lower mortality rates of around 7% at two years.7 Although patients with DCM were excluded from many early ICD studies, a ...
... 10–50% from referral centres, with up to 28% of deaths being classified as sudden.6 w2 More recent studies of DCM patients on optimal medical treatment have reported considerably lower mortality rates of around 7% at two years.7 Although patients with DCM were excluded from many early ICD studies, a ...
Circulatory System - Heart - Westgate Mennonite Collegiate
... Refractory Period • Absolute: Cardiac muscle cell completely insensitive to further stimulation • Relative: Cell exhibits reduced sensitivity to additional stimulation • Long refractory period prevents tetanic (continuous) contractions ...
... Refractory Period • Absolute: Cardiac muscle cell completely insensitive to further stimulation • Relative: Cell exhibits reduced sensitivity to additional stimulation • Long refractory period prevents tetanic (continuous) contractions ...
Study of left ventricular diastolic dysfunction in ischemic heart
... Adichunchanagiri Hospital and research centre from November 2012 to September 2014. Detailed history and physical examination was done. Every patient was subjected to ECG, CXR, routine investigations and Doppler Echo cardiography. Results: A total of 60 patients were studied. 23 patients showed dias ...
... Adichunchanagiri Hospital and research centre from November 2012 to September 2014. Detailed history and physical examination was done. Every patient was subjected to ECG, CXR, routine investigations and Doppler Echo cardiography. Results: A total of 60 patients were studied. 23 patients showed dias ...
Cardiovascular Alterations Discussion 1: Cardiovascular Alterations
... surgery is necessary to correct defects and contain heart valve disease. Clinical trial data have been used to recommend a dose-dependent improvement, LV function and has reduced mortality and hospitalizations of β-blocker users. Medical practitioners are obligated to conduct physical examinations o ...
... surgery is necessary to correct defects and contain heart valve disease. Clinical trial data have been used to recommend a dose-dependent improvement, LV function and has reduced mortality and hospitalizations of β-blocker users. Medical practitioners are obligated to conduct physical examinations o ...
Barostim: neo
... The system is minimally invasive and highly adaptable: • Single-side incision • Wirelessly monitored and controlled at physician’s office • Therapy can be adjusted to meet each patient’s individual needs as they change over time, providing personalized treatment and avoiding issues of non-compliance ...
... The system is minimally invasive and highly adaptable: • Single-side incision • Wirelessly monitored and controlled at physician’s office • Therapy can be adjusted to meet each patient’s individual needs as they change over time, providing personalized treatment and avoiding issues of non-compliance ...
Antiarrhythmic drugs
... Absolute refractory period: it is the period during which cardiac cells will not respond to any stimulus i.e. will not depolarize, it includes phase 1 and 2. Relative refractory period: include phase 3 the cell will depolarize only if the stimulus is unusually strong. Antiarrhythmic drugs Has been c ...
... Absolute refractory period: it is the period during which cardiac cells will not respond to any stimulus i.e. will not depolarize, it includes phase 1 and 2. Relative refractory period: include phase 3 the cell will depolarize only if the stimulus is unusually strong. Antiarrhythmic drugs Has been c ...
Heart Failure
... heart disease; from 400 to 800 gm (up to two to three times normal) in systemic hypertension, aortic stenosis, mitral regurgitation, or dilated cardiomyopathy; from 600 to 1000 gm (three or more times normal) in aortic regurgitation or hypertrophic cardiomyopathy. Hearts weighing more than 1000 gm a ...
... heart disease; from 400 to 800 gm (up to two to three times normal) in systemic hypertension, aortic stenosis, mitral regurgitation, or dilated cardiomyopathy; from 600 to 1000 gm (three or more times normal) in aortic regurgitation or hypertrophic cardiomyopathy. Hearts weighing more than 1000 gm a ...
Iodine-123 mIBG Imaging for Predicting the Development of Atrial
... They did not have the clinical symptoms of HF (10). The diagnosis of AF was made when visible P-waves on all 12 leads of ECG were absent, and an irregular random-appearing ventricular response was present (7). The AF was considered paroxysmal if the fibrillatory process ended spontaneously after som ...
... They did not have the clinical symptoms of HF (10). The diagnosis of AF was made when visible P-waves on all 12 leads of ECG were absent, and an irregular random-appearing ventricular response was present (7). The AF was considered paroxysmal if the fibrillatory process ended spontaneously after som ...
C 3. Determinants and control of cardiac output a. Explain Starling`s
... rise in cardiac output in order to maintain blood pressure. Myocardial contractility is increased by preload, heart rate (force-frequency relation), circulating catecholamines acting at cardiac ß1-receptors and inotropic agents such as digoxin and phosphodiesterase inhibitors. It is reduced by paras ...
... rise in cardiac output in order to maintain blood pressure. Myocardial contractility is increased by preload, heart rate (force-frequency relation), circulating catecholamines acting at cardiac ß1-receptors and inotropic agents such as digoxin and phosphodiesterase inhibitors. It is reduced by paras ...
Ventricular Assist Devices
... Two pulsatile devices, the HeartMate SNAP VE LVAS, and the HeartMate XVE LVAS, have received FDA approval as destination therapy. The Heartmate II LVAS, a continuous flow device received FDA approval as destination therapy January 20, 2010. The premarket approval included two-year data from a study ...
... Two pulsatile devices, the HeartMate SNAP VE LVAS, and the HeartMate XVE LVAS, have received FDA approval as destination therapy. The Heartmate II LVAS, a continuous flow device received FDA approval as destination therapy January 20, 2010. The premarket approval included two-year data from a study ...
CARDIOLOGY NURSING/ PRINCIPLES OF CARDIAC NURSING 6KNIR302/ 6KNIR304
... Late submissions will be accepted for 24 hours following the submission date. All work submitted late will be marked as normal but will be capped at the pass mark for the module. If your assignment is hard copy please ensure you date stamp it and submit it to the submission room G15 JCMB. If your as ...
... Late submissions will be accepted for 24 hours following the submission date. All work submitted late will be marked as normal but will be capped at the pass mark for the module. If your assignment is hard copy please ensure you date stamp it and submit it to the submission room G15 JCMB. If your as ...
Ppt
... – Coronary atherosclerosis – Persistent high blood pressure – Multiple myocardial infarcts ...
... – Coronary atherosclerosis – Persistent high blood pressure – Multiple myocardial infarcts ...
Pathophysiologic Basis for Health Deviations 437
... - Mode of response to sensed electrical impulses (inhibited or triggered) - Rate modulation - Multi site pacing ...
... - Mode of response to sensed electrical impulses (inhibited or triggered) - Rate modulation - Multi site pacing ...
Robust Detection of Premature Ventricular
... detection of CVD and the determination of the underlying etiology of the disease for prevention and treatment is therefore a crucial task. Identifying premature ventricular contractions (PVCs) in Holter recordings or during monitoring is of particular interest. PVCs result from irritated ectopic foc ...
... detection of CVD and the determination of the underlying etiology of the disease for prevention and treatment is therefore a crucial task. Identifying premature ventricular contractions (PVCs) in Holter recordings or during monitoring is of particular interest. PVCs result from irritated ectopic foc ...
prediction and prevention of sudden cardiac death in - Heart
... 10–50% from referral centres, with up to 28% of deaths being classified as sudden.6 w2 More recent studies of DCM patients on optimal medical treatment have reported considerably lower mortality rates of around 7% at two years.7 Although patients with DCM were excluded from many early ICD studies, a ...
... 10–50% from referral centres, with up to 28% of deaths being classified as sudden.6 w2 More recent studies of DCM patients on optimal medical treatment have reported considerably lower mortality rates of around 7% at two years.7 Although patients with DCM were excluded from many early ICD studies, a ...
CardioCase of the Month - STA HealthCare Communications
... individual should be screened for ARVD. This is used to establish the pattern of inheritance. Screening should begin during the teenage years unless otherwise indicated. Tests include: • Echocardiogram • ECG • Signal averaged ECG • Holter monitoring • Cardiac MRI • Exercise stress test ...
... individual should be screened for ARVD. This is used to establish the pattern of inheritance. Screening should begin during the teenage years unless otherwise indicated. Tests include: • Echocardiogram • ECG • Signal averaged ECG • Holter monitoring • Cardiac MRI • Exercise stress test ...
Restrictive Cardiomyopathy
... • Treat underlying disease in secondary causes • Attempt to maintain sinus rhythm, atrial fibrillation is poorly tolerated – Amiodarone ...
... • Treat underlying disease in secondary causes • Attempt to maintain sinus rhythm, atrial fibrillation is poorly tolerated – Amiodarone ...
Sudden Cardiac Death in Three Generations of the Same Family: A
... Every one of us has heard about tragic and sudden death of a healthy young person and which is often stated as ‘inexplicable’. The current case report focuses on a 20 year old young man with hypertrophic cardiomyopathy facing premature death with history of similar sudden premature death of his gran ...
... Every one of us has heard about tragic and sudden death of a healthy young person and which is often stated as ‘inexplicable’. The current case report focuses on a 20 year old young man with hypertrophic cardiomyopathy facing premature death with history of similar sudden premature death of his gran ...
Fatal cardiac arrhythmias in patients with heart failure: Risk
... 40 days post MI, there is no non-invasive or invasive strategy that can reliably predict SCD risk and guide ICD therapy, especially soon after MI. • For early post MI patients, the management directive is to maximize optimal medical therapy and revascularization (early if not primary), and reevaulat ...
... 40 days post MI, there is no non-invasive or invasive strategy that can reliably predict SCD risk and guide ICD therapy, especially soon after MI. • For early post MI patients, the management directive is to maximize optimal medical therapy and revascularization (early if not primary), and reevaulat ...
CorePace Module 8 - Pacemaker Patient Follow-up
... • Medtronic leads are contraindicated for the following: • ventricular use in patients with tricuspid valvular disease or a tricuspid mechanical heart valve. • patients for whom a single dose of 1.0 mg of dexamethasone sodium phosphate or dexamethasone acetate may be contraindicated. (includes all l ...
... • Medtronic leads are contraindicated for the following: • ventricular use in patients with tricuspid valvular disease or a tricuspid mechanical heart valve. • patients for whom a single dose of 1.0 mg of dexamethasone sodium phosphate or dexamethasone acetate may be contraindicated. (includes all l ...
management of cardiogenic shock and right heart failure
... • Inotropic therapy à for RV failure when CS persists ajer RV end-‐diastolic pressure has been ...
... • Inotropic therapy à for RV failure when CS persists ajer RV end-‐diastolic pressure has been ...
prompt diagnosis and management of acute heart failure syndrome
... The immediate goals of treatment in AHF are to improve symptoms and to stabilize haemodynamic condition especially oxygenation and tissue perfusion.5 Planning follow up strategy is needed in hospitalized patients and also long-term management if the acute episode leads to chronic HF. Initial treatme ...
... The immediate goals of treatment in AHF are to improve symptoms and to stabilize haemodynamic condition especially oxygenation and tissue perfusion.5 Planning follow up strategy is needed in hospitalized patients and also long-term management if the acute episode leads to chronic HF. Initial treatme ...
High Resolution MR Imaging of the Fetal Heart with Cardiac
... One of the greatest challenges in the fetal MR imaging is the evaluation of the fetal heart. Usually the cardiac imagings in adults are ECG triggered and is made with breathhold of the patient. Since the fetal heart lies within the uterus, a direct triggering of the heart frequency of the fetus is n ...
... One of the greatest challenges in the fetal MR imaging is the evaluation of the fetal heart. Usually the cardiac imagings in adults are ECG triggered and is made with breathhold of the patient. Since the fetal heart lies within the uterus, a direct triggering of the heart frequency of the fetus is n ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.